S'abonner

Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial - 30/06/26

Doi : 10.1016/S1470-2045(26)00120-8 
James P Buteau, MD a, b, Daniel Moon, MBBS c, d, Michael T Fahey, PhD e, Matthew J Roberts, PhD f, g, Narjess Ayati, MD h, i, Nathan Papa, PhD h, j, Declan G Murphy, ProfMBBCh b, c, Veeru Kasivisvanathan, ProfPhD c, k, l, Haryana M Dhillon, ProfPhD m, Yang T Du, MBBS n, Philip Dundee, FRACS d, Jessica Foudoulis, MHIM e, David Hennes, MD a, Anthony C Hutton, FRACS o, Jordan Idiare, MBBS h, Greg Jack, FRACS p, Sheshang Kamath, FRACS q, Sophie N Lee, PhD e, Su-Faye Lee, FRANZC a, Sze Ting Lee, ProfPhD r, Scott Leslie, MBBS s, t, Sidney M Levy, PhD a, b, Emma Link, DPhil e, Catherine Mitchell, MBBS b, x, Joshua J Morigi, MD v, Andrew Nguyen, MBBS h, i, Joanna Olphert, MClinEpi o, Manish I Patel, ProfPhD w, David A Pattison, ProfMBBS y, z, Adam Pearce, BM f, Marlon Perera, PhD b, c, p, Ruban Thanigasalam, MBBS s, u, Alice Thomson, MBBS c, John Yaxley, FRACS f, g, James Thompson, PhD o, Michael S Hofman, ProfMBBS a, b, *⁎ , Louise Emmett, ProfMD h, i, j, *
for the

PRIMARY2 Trial Investigators †

  PRIMARY2 Trial Investigators are listed in the Supplementary Material
Laura Adams, Tim J Akhurst, Omar Alghazo, Ramin Alipour, Narjess Ayati, Aries Balino, Ashley Baring, Salvatore Berlangieri, Madison Bills, Emma Boehm, Raef Boktor, Neeraja Bollampally, Caitlin Burt, James P Buteau, Emma Callegari, Anthony Cardin, Yee Chan, David C Chen, Tina Chen, Karla Cullen, Richard De Abreu Lourenco, Katrina Devitt, Nattakorn Dhiantravan, Haryana M Dhillon, Juliana Di Iulio, Yang T Du, Philip Dundee, Renu Eapen, Louise Emmett, David Ende, Michael T Fahey, Dulash Fernando, Jessica Foudoulis, Roslyn J Francis, Mark Frydenberg, Geetha Guduguntla, Gaurav Ghosh, Jeremy P Grummet, Simon Harley, David Hennes, Adam Hickey, Bao Ho, Michael S Hofman, Emily Hong, Anthony C Hutton, Jordan Idiare, Greg Jack, Kerry E Jewell, Nikeith John, Sheshang Kamath, Raghava K Kashyap, Veeru Kasivisvanathan, Sabina Kesuma, Umar Khan, Grace Kong, Natalia Kovaleva, Eddie Lau, Nathan Lawrentschuk, Dominic Lee, Jonathan Lee, Su-Faye Lee, Sze Ting Lee, Sophie N Lee, Scott Leslie, Sidney M Levy, Sherrington Li, William Lindeman, Karen Lindsay, Emma Link, Aoife McVey, Catherine Mitchell, Kate Moodie, Daniel Moon, Joshua J Morigi, Declan G Murphy, Ben Namdarian, Ghazala Naureen, Alexander Nesbitt, Andrew Nguyen, Gaia Ninatti, Monica O’Neill, Jonathan O’Brien, Joanna Olphert, Nathan Papa, Leeanne Pasanen, Manish Patel, David A Pattison, Adam Pearce, Marlon Perera, Elisa Perry, Sruit Pillai, Aurora Poon, Weranja Ranasinghe, Aravind S Ravi Kumar, Matthew J Roberts, Javad Saghebi, Stephen Schlicht, Andrew M Scott, Clare Senko, Shekib Shahbaz, Jeremy Shapiro, Shikha Sharma, Gaurav Sharma, Gemma Sheehan-Dare, Edward Shen, Dinesh Sivaratnam, Ross Smith, Stephen Stuckey, Jo-Lynn Tan, Andrew Tauro, Ruban Thanigasalam, James Thompson, Alice Thomson, Jehan Titus, Leyna Tran, Christer W Valeriano, Sytse Van Beek, Daniel Valenzuela, Michela Vermeulen, Jess Watson, Shraddha Weir, David Wetherell, Aaron Jun Ning Wong, Keith Wong, Kelvin Yap, John Yaxley, Alex Zheng

a Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia 
b Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia 
c Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia 
d University of Melbourne, Royal Melbourne Clinical School, Melbourne, VIC, Australia 
e Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia 
f Department of Urology, Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia 
g Faculty of Health, Medicine and Behavioural Sciences, University of Queensland, Brisbane, QLD, Australia 
h Department of Theranostics and Nuclear Medicine, St Vincent’s Hospital, Sydney, NSW, Australia 
i St Vincent’s Clinical School, University of New South Wales, Sydney, NSW, Australia 
j Garvan Institute of Medical Research, Sydney, NSW, Australia 
k Division of Surgery and Interventional Science, University College London, London, UK 
l Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria 
m Psycho-Oncology Cooperative Research Group, School of Psychology, Faculty of Science, The University of Sydney, Sydney, NSW, Australia 
n Department of Nuclear Medicine, PET and Bone Densitometry, Royal Adelaide Hospital, Adelaide, SA, Australia 
o St George Clinical School, University of New South Wales, Sydney, NSW, Australia 
p Department of Surgery, Austin Health, Melbourne, VIC, Australia 
q Department of Urology, Royal Darwin Hospital, Darwin, NT, Australia 
r Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia 
s Department of Urology, Chris O’Brien Lifehouse, Sydney, NSW, Australia 
t Faculty of Medicine, University of Sydney, Sydney, NSW, Australia 
u Concord Clinical School, University of Sydney, Sydney, NSW, Australia 
v Molecular Imaging Unit, Royal Darwin Hospital, Darwin, NT, Australia 
w Department of Urology, Westmead Hospital, University of Sydney, Sydney, NSW, Australia 
x Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia 
y Department of Nuclear Medicine and PET Services, Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia 
z School of Medicine, University of Queensland, Brisbane, QLD, Australia 

* Correspondence to: Prof Michael S Hofman, Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC) Molecular Imaging and Therapeutic Nuclear Medicine Cancer Imaging Peter MacCallum Cancer Centre Melbourne VIC 3000 Australia

Summary

Background

MRI is recommended for men with clinical suspicion of significant prostate cancer. Those with high clinical risk but non-suspicious or equivocal MRI often undergo prostate biopsy, but have a low likelihood of clinically significant prostate cancer, and a high incidence of clinically insignificant prostate cancer. We aimed to investigate whether gallium-68 ([ 68 Ga]Ga)-prostate-specific membrane antigen (PSMA)-11 PET-CT could reduce the number of people requiring prostate biopsy and limit biopsy to targeted cores, without compromising clinically significant prostate cancer diagnosis.

Methods

In this multicentre, non-inferiority, phase 3, randomised controlled trial, done at at seven Australian hospitals, we recruited biopsy-naive participants with clinical suspicion of significant prostate cancer, equivocal (Prostate Imaging-Reporting and Data System [PI-RADS] 3) or non-suspicious (PI-RADS 2) MRI but high clinical risk (eg, prostate-specific antigen [PSA] density of > 0·1 ng/mL/mL, strong family history of prostate cancer, abnormal digital rectal examination, BRCA mutation, PSA > 10 ng/mL, PSA doubling time < 36 months, or PSA velocity > 0·75 ng/mL per year), PSA of 20 ng/mL or less, and clinical T2 disease or less. Participants were randomly assigned (1:1) using a centralised web-based system to undergo [ 68 Ga]Ga-PSMA-11 PET-CT (experimental group) or systematic transperineal prostate biopsy (control group), using block sizes of two or four and stratification by study site. There was no masking for participants or investigators. Participants with positive [ 68 Ga]Ga-PSMA-11 PET-CT (PRIMARY score 3–5) underwent PSMA-PET-targeted transperineal prostate biopsies, whereas those with a negative result (PRIMARY score 1–2) avoided biopsy. The co-primary outcomes were the proportion of participants with clinically significant prostate cancer, defined as a Gleason score of 3 + 4 (≥10% pattern 4) or higher, and the proportion of participants in the [ 68 Ga]Ga-PSMA-11 PET-CT group who avoided biopsy within 6 months of random assignment. A two-sided 95% Wald CI based on a binomial model was used to estimate the risk difference in the proportion of participants with clinically significant prostate cancer (non-inferiority margin 10%) and to estimate the proportion of participants in the experimental group who had avoided biopsy 6 months after random assignment (20% threshold), analysed based on intention to treat. This trial is registered with ClinicalTrials.gov , NCT05154162 , and participant follow-up is ongoing.

Findings

Between March 2, 2022, and Aug 24, 2025, 660 eligible male participants were enrolled and had a median age of 61 years (IQR 56–66), a median PSA of 5·2 ng/mL (4·0–7·0), and a median PSA density of 0·13 ng/mL/mL (0·09–0·17). There were PI-RADS 2 in 335 (51%) participants and PI-RADS 3 in 325 (49%) participants. Ethnicity data were not collected. 329 (50%) were assigned to the control group with systematic transperineal prostate biopsy, and 331 (50%) were assigned to the experimental group with [ 68 Ga]Ga-PSMA-11 PET-CT. The proportion of participants with clinically significant prostate cancer in the experimental group (39 [12%] of 331) was non-inferior to the control (51 [16%] of 329; difference –3·7% [95% CI –8·9 to 1·5%]; p=0·0093). Use of [ 68 Ga]Ga-PSMA-11 PET-CT avoided biopsy in 163 (49%) of 331 participants (95% CI 44 to 55%; p < 0·0001). After prostate biopsy, participants reported similar proportions of pain (33 [21%] in the experimental group vs 62 [21%] in the control group), haematuria (60 [38%] vs 126 [43%]), and haematospermia (77 [48%] vs 133 [45%]).

Interpretation

[ 68 Ga]Ga-PSMA-11 PET-CT could have the potential to improve the diagnostic pathway of patients with a high clinical risk but non-suspicious or equivocal prostate MRI. Further research, including health-economic analyses and validation with other PSMA radiopharmaceuticals, are needed to confirm the clinical implementation and generalisability of this approach.

Funding

Prostate Cancer Foundation, National Health and Medical Research Council, St Vincent’s Curran Foundation, and Peter MacCallum Cancer Foundation.

Le texte complet de cet article est disponible en PDF.

Plan


© 2026  The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 27 - N° 7

P. 839-848 - juillet 2026 Retour au numéro
Article précédent Article précédent
  • SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial
  • Giulio Francolini, Vanessa Di Cataldo, Saverio Caini, Pietro Garlatti, Michele Aquilano, Niccolò Bertini, Alessio Bruni, Gianluca Ingrosso, Rolando M D’Angelillo, Luca Tagliaferri, Barbara A Jereczek-Fossa, Matteo Augugliaro, Luca Triggiani, Silvana Parisi, Lorenzo Masieri, Riccardo Campi, Richard K Valicenti, Gabriele Simontacchi, Daniela Greto, Pierluigi Bonomo, Mauro Loi, Chad Tang, Lorenzo Livi, ARTO Working Group, Giulia Marvaso, Filippo Alongi, Andrea Gaetano Allegra, Andrea Lancia, Fabio Arcidiacono, Annamaria Vinciguerra, Ciro Franzese, Giorgia Timon, Cinzia Iotti, Monica Mangoni, Isacco Desideri, Icro Meattini, Carlotta Becherini, Raffaela Doro, Laura Masi
| Article suivant Article suivant
  • Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a randomised, open-label, phase 3 trial
  • Koen P Rovers, Checca Bakkers, Teun B M van den Heuvel, Vincent C J van de Vlasakker, Teun M E Kerkhoff, Simon W Nienhuijs, Jacobus W A Burger, Geert-Jan M Creemers, Irene E G van Hellemond, Jurriaan B Tuynman, Miranda Kusters, Tineke E Buffart, Arend G J Aalbers, Niels F M Kok, Myriam Chalabi, Djamila Boerma, Alexandra R M Brandt-Kerkhof, Philip R de Reuver, Patrick H J Hemmer, Wilhelmina M U van Grevenstein, Kurt van der Speeten, Petur Snaebjornsson, Pui Yuen Lee-Law, Max J Lahaye, Joost Nederend, Onno Kranenburg, Jeanette M Bouma, Cornelis J A Punt, Marcel G W Dijkgraaf, Pieter J Tanis, Ignace H J T de Hingh, CAIRO6 Investigators, Dutch Peritoneal Oncology Group and the Dutch Colorectal Cancer Group

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.